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A chalcone derivative reactivates 
latent HIV-1 transcription through 
activating P-TEFb and promoting 
Tat-SEC interaction on viral 
promoter
Jun Wu1, Ming-tao Ao1, Rui Shao1, Hui-ru Wang1, Diao Yu1, Mei-juan Fang1, Xiang Gao1,  
Zhen Wu1, Qiang Zhou2 & Yu-hua Xue1
The principal barrier to the eradication of HIV/AIDS is the existence of latent viral reservoirs. One 
strategy to overcome this barrier is to use latency-reversing agents (LRAs) to reactivate the latent 
proviruses, which can then be eliminated by effective anti-retroviral therapy. Although a number of 
LRAs have been found to reactivate latent HIV, they have not been used clinically due to high toxicity 
and poor efficacy. In this study, we report the identification of a chalcone analogue called Amt-87 
that can significantly reactivate the transcription of latent HIV provirses and act synergistically with 
known LRAs such as prostratin and JQ1 to reverse latency. Amt-87 works by activating the human 
transcriptional elongation factor P-TEFb, a CDK9-cyclin T1 heterodimer that is part of the super 
elongation complex (SEC) used by the viral encoded Tat protein to activate HIV transcription. Amt-87 
does so by promoting the phosphorylation of CDK9 at the T-loop, liberating P-TEFb from the inactive 
7SK snRNP, and inducing the formation of the Tat-SEC complex at the viral promoter. Together, our 
data reveal chalcones as a promising category of compounds that should be further explored to identify 
effective LRAs for targeted reversal of HIV latency.
The latent HIV reservoir, which contains integrated but transcriptionally silent proviruses, is the principal obsta-
cle to the eradication of HIV/AIDS1, 2. Effective curative strategies aiming at eliminating the reservoir are being 
developed3–9. One such strategy, nicknamed “shock and kill”, proposes to reactivate the latent HIV proviruses 
with latency-reversing agents (LRAs) in the initial “shock” phase. This is followed in the “kill” phase by the use 
of highly active anti-retroviral therapy (HAART) to prevent new infections and at the same time by making the 
reactivated cells sensitive to the host immune system and viral cytopathogenicity10–12. The implementation of the 
“shock and kill” strategy has so far been hindered by the lack of clinically effective LRAs. All the available LRAs 
such as the HDAC inhibitor SAHA, PKC agonist prostratin and BET bromodomain inhibitor JQ1 are either 
highly toxic or display poor clinical outcomes13–15. Thus, high efficacious and specific drugs for reactivating latent 
HIV are urgently needed.
The reactivation of latent proviral transcription requires the HIV-encoded trans-activator protein Tat, which 
stimulates the elongation stage of RNA polymerase (Pol) II transcription to produce the full-length viral tran-
scripts14. Tat acts by recruiting the host super elongation complex (SEC) containing CDK9, cyclin (Cyc)T1, AFF1 
or AFF4, ELL1 or ELL2, and AF9 or ENL to the viral TAR RNA element, which is a stem-loop structure formed 
at the 5′ end of the nascent HIV transcript16, 17. Once recruited, the SEC components CDK9 and CycT1, which 
forms a heterodimer referred to as P-TEFb, phosphorylates the C-terminal domain of the largest subunit of Pol II 
and a pair of negative elongation factors DSIF and NELF, leading to the release of Pol II from promoter-proximal 
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pausing. On the other hand, the ELL1/2 subunit of the SEC can also directly stimulate the processivity of Pol II by 
suppressing transient pausing. Thus, working from a single Tat-SEC complex, P-TEFb and ELL1/2 can synergis-
tically activate Pol II elongation along the provial DNA to reverse HIV latency18–21.
In latently infected T cells, the vast majority of P-TEFb is sequestered in a catalytically inactive complex called 
the 7SK snRNP4. In addition to P-TEFb, this 7SK snRNP also contains the 7SK snRNA that acts as a molecular 
scaffold to hold the complex together and the HEXIM protein, which functions as an inhibitor of CDK917, 22–25. 
Within the 7SK snRNP, the-La related protein LARP7 and the 7SK snRNA capping enzyme MePCE are also 
constitutive components, which stabilize the 7SK snRNA and may also be involved in regulating the release of 
P-TEFb26–29. The sequestration of P-TEFb in 7SK snRNP keeps the overall P-TEFb/SEC activity in a cell at a very 
low level and has been proposed as a key factor contributing to HIV latency26.
Chalcones, also known as chalconoids, are aromatic ketones that contain two phenyl rings and often emerge 
as intermediates in the synthesis of many biological compounds. They have been shown to possess an array of 
biological activities including anti-inflammatory, antioxidant, antitumor and antibacterial activities and can also 
inhibit angiogenesis in vivo and in vitro30–35. Chalcone analogues have attracted a great deal of interest due to their 
synthetic and biological importance in medicinal chemistry36. Recently, in a screen for LRAs that can reverse HIV 
latency, we have come upon a series of 2′-hydroxy-5-adamantyl-chalcones that display such an activity. One of 
them, called Amt-87, dose-dependently activates HIV transcription while displaying only mild cytotoxicity. It can 
also synergize with traditional LRAs such as prostratin and JQ1 to reactivate latent proviruses. Mechanistically, 
Amt-87 is shown to increase the phosphorylation of the CDK9 T-loop at position Thr186, dissociate P-TEFb 
from 7SK snRNP, and promote the assembly of the Tat-SEC complex on the HIV-1 LTR. Together, these data have 
revealed chalcones as a promising category of compounds that should be further explored to identify effective 
LRAs for targeted reversal of HIV latency.
Results
Identification of Amt-87 as a HIV latency-reversal agent (LRA). To identify LRAs that can effectively 
reverse HIV latency, a systematic screen for compounds or natural products present in a library established in 
the School of Pharmaceutical Sciences at Xiamen University was conducted. This library contained chemically 
synthesized compounds as well as purified native products derived from traditional Chinese medicinal herbs, 
marine microbial secondary metabolites, and symbiotic bacteria secondary metabolites37. For detection of latency 
reversal, we employed the Jurkat T cell line-based J-Lat A2 system, which contains an integrated HIV-1 5′-LTR-
Tat-Flag-iRES-EGFP-3′-LTR expression cassette38. This cassette is normally silent but produces the enhanced 
green fluorescent protein (GFP) upon activation, which can be detected by flow cytometry (FACS).
Among a family of structurally related chalcone derivatives, we found that significant induction of GFP 
expression in J-Lat A2 cells, i.e. reversal of HIV-1 latency, was caused by members 1a, 1d, 1h, and 1l (Table 1). The 
general method for the synthesis of 2′-hydroxy-chalcone amide derivatives (1a–1p) is outlined in Supplemental 
Information (Supplementary Fig. S1). Unfortunately, all four also markedly reduced cell viability (Table 2). To 
decrease the toxicity of these compounds and at the same time preserve their latency-reversing potential, we 
generated another two series of chalcone derivatives with functional group adamant (Ad) at the C5-position of 
the benzene ring system (3a–3d and 4a–4d, see Table 1). Among these new derivatives, compound 3d [(E)-3-
(5-(adamantan-1-yl)-2,4-bis(methoxymethoxy) phenyl)-1-(2-hydroxy-5-methylphenyl)prop-2-en-1-one], called 
Amt-87 henceforth, effectively induced GFP production in J-Lat A2 cells at 50 and 100 μg/mL, while displaying 
significantly diminished cell toxicity at these concentrations compared to compounds in the other series (Table 2).
The chemical structure of Amt-87 is shown in Fig. 1A and its purity was confirmed by High-Performance 
Liquid Chromatography with Diode-Array Detection (HPLC-DAD) performed at 254 nm (up) and 280 nm 
(down) in Fig. 1B, as well as the examination by 1H-NMR (left) and13C-NMR (right) in Fig. 1C. The general 
chemistry of the synthesis of Amt-87 is outlined in Supplemental Information (Supplementary Fig. S2). To fur-
ther determine whether Amt-87 may affect cell growth, we used the Promega CellTiter-Glo® Luminescent Cell 
Viability Assay kit to measure the viability of both J-Lat A2 and HeLa cells that were treated with Amt-87 at con-
centrations of 50, 100 and 200 μg/mL for 24 hours. As indicated in Fig. 1D, these concentrations had no or only 
a very minor effect on the viability of HeLa cells when compared with the empty vehicle DMSO. For J-Lat A2, 
although these cells were more sensitive to Amt-87, treatment with 50 ug/ml of the drug, which was used in most 
latency-reversal experiments described below, had a relatively mild effect on cell viability.
Based on the above results showing that among the entire collection of chalcone derivatives, Amt-87 displayed 
the most optimal properties in terms of its efficient latency-reversing activity and relatively mild cytotoxicity, it 
was thus selected for further mechanistic study as outlined below.
Amt-87 reactivates latent HIV at the transcriptional level. When J-Lat A2 cells were treated with 
different amounts of Amt-87 and for various time periods, the percentage of GFP-positive cells increased in a 
dose- and time-dependent manner (Fig. 2A,B). In addition, the treatment also significantly augmented the mean 
fluorescence intensity (MFI) of the GFP-positive cells (Supplementary Fig. S3). To confirm that the enhanced GFP 
signal detected by FACS was due to the increased production of GFP mRNA, quantitative RT-PCR (qRT-PCR) 
with primers that hybridize to a distal portion of the GFP gene was performed. The result showed that Amt-87 
indeed reactivated the HIV provirus through stimulating the LTR-driven mRNA production (Fig. 2C), suggesting 
that the activation occurred at the transcriptional level.
The 2D10 cell line is another Jurkat-based post-integrative latency model that harbors almost the complete 
HIV genome except for the nef gene that is replaced by the GFP-coding sequence39. Importantly, the stimulatory 
effect of Amt-87 to reactivate latent HIV was also confirmed in this system (Fig. 2D). Finally, to ensure that the 
Amt-87-induced HIV transactivation was dependent on the viral 5′-LTR but not any other unrelated viral or 
non-viral sequences in the integrated expression cassette, we tested the effect of Amt-87 on expression of an 
www.nature.com/scientificreports/
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Compound
Structures % GFP(+) 
cells (50 μg/
mL) Compound
Structures % GFP(+) 
cells (50 
μg/mL)R′ R R′ R
DMSO 0.7 ± 0.1 1o 2′-OH-4′-CH3 3-CONHCH2CH2-3′-Thi 3.1 ± 1.3
Prostratin (2.5 
μm) 65.3 ± 5.4 1p 2′-OH-4′-CH3 3-CONHCH2CH2Ph 1.8 ± 0.3
1a 2′-OH-5′-CH3 4-CONHCH2CH2-3′-Thi 10.3 ± 2.0 2a 2′-OH 2-OH 2.0 ± 0.2
1b 2′-OH-5′-CH3 4-CONHPh 4.0 ± 1.5 2b 2′-OH 4-OH 1.2 ± 0.1
1c 2′-OH-5′-CH3 4-CONHCH2Ph — 2c 2′4′-OH 4-OH 1.3 ± 0.2
1d 2′-OH-5′-CH3 4-CONH(CH2)2Ph 14.3 ± 3.3 2d 2′-OH-5′-CH3 4-OH 0.7 ± 0.2
1e 2′-OH-5′-CH3 4-CONH(CH2)3Ph — 2e 4′-OH 2-OH-6-OCH3-3-prenyl 1.0 ± 0.2
1f 2′-OH-5′-CH3 4-CONH(CH2)4Ph 4.2 ± 1.1 3a 2′-OH 4-MOM-5-Ad —
1g 2′-OH-5′-CH3 4-CONHCH2-1-Nap 2.6 ± 1.0 3b 2′-OH-5′-Cl 4-MOM-5-Ad —
1h 2′-OH-5′-CH3 4-CONHPh-2′-OCH3 20.7 ± 3.8 3c 2′-OH-5′-CH3 4-MOM-5-Ad 3.9 ± 1.0
1i 2′-OH-5′-CH3 4-CONHC(CH3)3 — 3d (Amt-87) 2′-OH-5′-CH3 2,4-diMOM-5-Ad 4.9 ± 1.6
1j 2′-OH-5′-CH3 4-CONH-cyclo-C4H7 — 3e 5′-CH3 2,4-diMOM-5-Ad —
1k 2′-OH-5′-CH3 4-CONH(CH2)5CH3 4.1 ± 1.2 4a 2′-OH 4-OH-5-Ad —
1l 2′-OH-5′-CH3 4-CONH(CH2)7CH3 6.5 ± 1.4 4b 2′-OH-5′-Cl 4-OH-5-Ad —
1m 2′-OH-5′-CH3 4-CONH-cyclo-C8H15 — 4c 2′-OH-5′-CH3 4-OH-5-Ad 3.5 ± 0.7
1n 2′-OH-5′-CH3 4-CONH-1-Ad 1.5 ± 0.2 4d 2′-OH-5′-CH3 2,4-OH-5-Ad —
Table 1. Reactivation of latent HIV-1 gene expression by the indicated chalconoids in J-Lat A2 cells. J-Lat A2 
cells were treated for 24 hr with the empty vehicle DMSO, prostratin (2.5 μM) or the various chalconoids (50 μg/
mL) of the indicated structures. Levels of HIV latency reversal were evaluated by FACS analysis to measure the 
percentage of cells that displayed the HIV LTR-driven GFP production. Data are presented as mean ± SD from 
at least three independent experiments performed in triplicates.
Compound R″
% GFP(+) cells (μg/mL) % Cell viability (μg/mL)
25 50 100 25 50 100
1a 4-CONHCH2CH2-3′-Thi 6.6 ± 0.7 9.2 ± 2.3 8.3 ± 1.6 67.1 ± 6.8 54.3 ± 5.4 41.8 ± 4.2
1b 4-CONHPh 3.1 ± 0.6 3.6 ± 1.2 3.0 ± 0.8 31.5 ± 4.4 15.7 ± 3.1 7.9 ± 2.2
1d 4-CONH(CH2)2Ph 13.7 ± 1.6 15.1 ± 2.4 15.7 ± 2.1 36.9 ± 3.9 35.0 ± 2.6 28.9 ± 3.7
1f 4-CONH(CH2)4Ph 2.5 ± 0.7 4.0 ± 1.3 7.2 ± 1.3 68.8 ± 3.1 65.2 ± 4.2 58.5 ± 4.5
1g 4-CONHCH2-1-Nap 10.3 ± 2.0 2.8 ± 1.0 1.8 ± 0.8 37.2 ± 6.2 27.9 ± 3.2 9.5 ± 1.5
1h 4-CONH-Ph-2′-OCH3 18.3 ± 1.3 22.5 ± 3.4 33.7 ± 3.6 49.3 ± 5.3 42.7 ± 4.0 12.3 ± 2.1
1k 4-CONH(CH2)5CH3 3.7 ± 1.2 3.9 ± 1.1 3.1 ± 1.0 67.6 ± 3.2 63.2 ± 4.2 53.3 ± 3.6
1l 4-CONH(CH2)7CH3 7.1 ± 1.7 8.4 ± 1.4 6.7 ± 1.5 24.7 ± 2.3 24.3 ± 2.7 19.5 ± 2.1
1o 3-CONHCH2CH2-3′-Thi 0.8 ± 0.1 3.8 ± 1.2 0.7 ± 0.1 36.4 ± 2.3 34.8 ± 2.7 37.3 ± 3.4
1p 3-CONH(CH2)2Ph 0.9 ± 0.1 2.1 ± 0.2 0.6 ± 0.1 42.0 ± 4.4 31.1 ± 2.0 31.2 ± 3.2
3c 4-MOM-5-Ad 0.7 ± 0.1 4.3 ± 1.1 13.3 ± 1.8 95.3 ± 3.5 92.5 ± 4.3 68.4 ± 4.2
3d (Amt-87) 2,4-diMOM-5-Ad 0.8 ± 0.1 5.9 ± 1.5 38.0 ± 4.2 96.3 ± 3.8 91.5 ± 3.4 72.9 ± 4.9
4c 4-OH-5-Ad 0.7 ± 0.1 3.8 ± 0.7 11.2 ± 2.0 86.4 ± 3.7 68.9 ± 6.3 45.4 ± 5.1
Table 2. Viability and GFP production in J-Lat A2 cells treated with the indicated chalconoids. J-Lat A2 cells 
were treated with the indicated compounds at 25, 50 and 100 μg/mL concentrations for 24 hr and the percentage 
of GFP(+) cells and cell viability were evaluated by FACS and Cell viability analysis, respectively. Data are 
presented as mean ± SD from at least three independent experiments that were performed in triplicates.
www.nature.com/scientificreports/
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integrated luciferase reporter gene that is driven solely by the HIV-1 5′-LTR in a pair of HeLa-based isogenic 
cells lines, NH1 and NH2, both of which contain an integrated HIV-1 5′ -LTR-luciferase reporter gene but only 
the latter stably expresses HIV-1 Tat40, 41. When these cells were treated with different amounts of Amt-87 and for 
various time periods as indicated in Fig. 2E–H, Amt-87 displayed a stimulatory effect on both Tat-independent 
and –dependent HIV-1 transcription in a dose- and time-dependent manner.
Amt-87 synergizes with conventional LRAs prostratin and JQ1 to reactivate latent 
HIV. Previous studies have identified several classes of chemical compounds that can reactivate latent HIV. For 
example, prostratin is the prototype of protein kinase C (PKC) agonist that acts through and NF-κB pathway to 
promote the recruitment of RNA Pol II to the HIV-1 LTR42. On the other hand, JQ1, a BET bromodomain inhib-
itor, induces the reversal of HIV latency through antagonizing the inhibitory action of Brd4 on Tat-dependent 
activation of HIV transcriptional elongation43. To investigate how Amt-87 might work together with these two 
known conventional LRAs, J-Lat A2 cells were treated with Amt-87 alone or in combination with prostratin 
(Fig. 3A) or JQ1 (Fig. 3B). The data indicate that the combined treatments produced a much greater percentage 
of GFP(+) cells than the simple sum of the effects produced by either compound alone. Notably, the synergism 
displayed by Amt-87 together with prostratin or JQ1 was also recapitulated in NH1 cells containing the integrated 
HIV-1 LTR-driven luciferase reporter gene (Fig. 3C,D).
CDK9 kinase activity is required for Amt-87 to reverse HIV latency. P-TEFb, which is composed 
of CDK9 and CycT1, plays a key role in HIV transcriptional activation, and its sequestration in the inactive 7SK 
snRNP has been proposed to contribute to viral latency15. To determine whether the kinase activity of CDK9 is 
required for Amt-87 to induce latency reversal, J-LatA2 cells were pre-treated with the CDK9 inhibitor flavopir-
idol44 or the more selective CDK9 inhibitor iCDK945 before the incubation with Amt-87. As shown in Fig. 4A,B, 
these two drugs completely blocked the reactivation of HIV latency induced by Amt-87.
The dependence on CDK9 kinase activity for Amt-87′s stimulatory effect was also observed in NH1 cells, 
where the pre-treatment with not only flavopiridol (Fig. 4C) but also iCDK9 (Fig. 4D) markedly suppressed the 
ability of Amt-87 to activate the LTR-driven luciferase expression. Finally, similar to these two small molecule 
inhibitors of CDK9, D167N, a dominant negative form of CDK946, was also able to prevent Amt-87 from acti-
vating the HIV-1 LTR once overexpressed in NH1 cells (Fig. 4E). Taken together, these dates indicate that the 
reversal of HIV latency by Amt-87 depended on CDK9’s kinase activity.
Figure 1. Purity analysis, structure confirmation and effect on cell viability of compound Amt-87. (A) The 
chemical structure of Amt-87 showing atom numbering. (B) HPLC-DAD analysis of Amt-87 performed at 
254 nm (up) and 280 nm (down) is presented. The purity of Amt-87 is estimated to be above 98%. (C) The 
1H-NMR (left) and 13C-NMR (right) spectra of Amt-87 are shown. The peaks in the spectra are identified and 
assigned to the structure. (D) The impact of Amt-87 on viability of J-Lat A2 and HeLa cells was measured at the 
indicated time points after the commencement of treatment by using the Promega CellTiter-Glo® Luminescent 
Cell Viability Assay kit. The error bars represent mean ± SD from three independent experiments.
www.nature.com/scientificreports/
5ScIenTIFIc RepoRts | 7: 10657  | DOI:10.1038/s41598-017-10728-w
Amt-87 promotes CDK9 T-loop phosphorylation. Given the above demonstrations that the stimulatory 
effect of Amt-87 depends on the active P-TEFb and the fact that the activation of P-TEFb during transcription 
elongation requires the phosphorylation of CDK9 on Thr186 at the T-loop47, 48, we next examined the phospho-
rylation status of Thr186 in NH1 and J-LatA2 cells after the treatment with Amt-87. Western analysis employ-
ing the phospho-Thr186 (pThr186)-specific antibody47, revealed that the level of phosphorylation on the CDK9 
T-loop significantly increased upon the treatment in both cell lines (Fig. 5A).
In order to release Pol II from promoter-proximal pausing, active P-TEFb is known to phosphorylate the Pol 
II CTD on Ser2 and the Spt5 subunit of DSIF on Thr77545. We next performed Western blotting analysis using 
phospho-specific antibodies to examine the effect of Amt-87 on the phosphorylation status at these two positions. 
As shown in Fig. 5B, Amt-87 increased the levels of both pSer2 and pThr775, and this increase was abolished 
when CDK9 activity was inhibited by flavopiridol. Collectively, these data demonstrate that Amt-87 reactivated 
HIV latency through enhancing the phosphorylation of the CDK9 T-loop at Thr186, which turned on P-TEFb’s 
kinase activity to phosphorylate Pol II CTD on Ser2 and DSIF Spt5 on Thr775 to activate HIV transcriptional 
elongation.
Amt-87 induces P-TEFb dissociation from 7SK snRNP and promotes Tat-SEC formation on 
HIV-1 LTR. In latently infected cells, most of the cellular P-TEFb are sequestered in the inactive 7SK snRNP, 
and the release of P-TEFb from this complex is essential for latency reactivation4. Since Amt-87 has been shown 
above to activate P-TEFb by causing Thr186 phosphorylation on CDK9, we asked whether this drug is capable 
of inducing P-TEFb’s dissociation from 7SK snRNP. To answer this question, anti-Flag immunoprecipitation was 
Figure 2. Amt-87 promotes reversal of HIV latency in a time- and does-dependent manner. (A,B) J-LatA2 
cells were treated with 50 μg/ml of Amt-87 for the indicated time periods (A) or the indicated concentrations 
of the drug for 24 hr (B). The percentages of cells expressing GFP were measured by FACS and plotted. (C) 
J-LatA2 cells were treated with DMSO or 200 μg/ml Amt-87 for 24 hr. The GFP mRNA levels were measured 
by qRT-PCR and normalized to those of GAPDH and plotted, with the value in DMSO-treated cells adjusted 
to 1. (D) Jurkat 2D10 cells were treated with 100 μg/ml of Amt-87 or DMSO for 24 hr and the expression of 
GFP was analyzed by FACS and plotted. (E,F) The HeLa-based NH1 cells containing an integrated HIV LTR-
luciferase reporter gene were treated with 100 μg/ml of Amt-87 for the indicated time periods (E) or 24 hr with 
the indicated concentrations of the drug (F). (G,H) The NH2 cells expressing Tat were treated with 100 μg/ml 
of Amt-87 for the indicated time periods (G) or 24 hr with in indicated concentrations of the drug (H). Whole 
cell extracts were prepared and examined for the luciferase activities. The error bars in all panels represent 
mean ± SD based on at least three independent experiments.
www.nature.com/scientificreports/
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performed in the HeLa-based F1C2 cells, which stably express the Flag-tagged CDK9 (CDK9-Flag)41, to examine 
the association of CDK9 with two signature 7SK snRNP components HEXIM1 and LARP7, which inhibits the 
CDK9 kinase activity and binds to the 3′ end of 7SK snRNA, respectively49. Using DMSO as a negative control, 
Figure 3. Amt-87 synergizes with prostratin and JQ1 to reverse HIV latency and reactivate viral transcription. 
(A,B) J-LatA2 cells were pretreated with prostratin (A) or JQ1 (B) for 2 hr, incubated with the indicated 
concentrations of Amt-87 for 24 hr, and then analyzed by FACS to determine the percentages of GFP(+) 
cells. (C,D) NH1 cells were pretreated with prostratin (A) or JQ1 (B) for 2hr, incubated with the indicated 
concentrations of Amt-87 for 24 hr, and then analyzed by FACS to determine the percentages of GFP(+) 
cells. Whole cell extracts (WCE) were examined for luciferase activities. The error bars in all panels represent 
mean ± SD from three independent experiments.
www.nature.com/scientificreports/
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we found that Amt-87 markedly reduced the amounts of HEXIM1 and LARP7 bound to the immunoprecipitated 
CDK9-Flag (Fig. 6A), indicating a disruption of the 7SK snRNP in Amt-87-treated cells.
Given the ability of Amt-87 to directly disrupt 7SK snRNP and activate P-TEFb, we next investigated whether 
the released P-TEFb can be recruited by HIV-1 Tat into a SEC to form the Tat-SEC complex for activation of HIV 
transcription and latency reversal. Indeed, anti-Flag immunoprecipitates derived from the HeLa-based NH1 cells 
expressing Tat-Flag showed increased associations of the signature SEC components AFF4, ELL2, ENL, CDK9 
and CycT1 with Tat-Flag upon the exposure to Amt-87 (Fig. 6B), suggesting an enhanced interaction between Tat 
and the SEC in Amt-87-treated cells.
To determine whether the enhanced Tat-SEC formation promoted by Amt-87 would result in an increased 
occupancy of the SEC at the HIV-1 promoter region, we performed the ChIP-qPCR analysis to examine the 
levels of CDK9, AFF4, ELL2 as well as the key 7SK snRNP subunit HEXIM1 at three separate locations along 
the integrated HIV-1 LTR-luciferase reporter gene. Indeed, compared to DMSO, Amt-87 increased the bindings 
of SEC components ELL2 and AFF4 as well as CDK9 at and around the HIV-1 promoter region, and decreased 
the binding of HEXIM1 especially at the HIV-1 promoter (Fig. 6C). These results are consistent with the notion 
that P-TEFb is transferred from the 7SK snRNP to the SEC in the presence of Amt-87. Taken together, these data 
support the model that by promoting T-loop phosphorylation in CDK9 and release of P-TEFb from 7SK snRNP, 
Amt-87 can increase the active pool of P-TEFb in the nucleus for formation of more Tat-SEC at the HIV-1 LTR, 
which in turn activates HIV-1 transcription and reverses viral latency.
Figure 4. The kinase activity CDK9 is essential for Amt-87 to reactivate latent HIV-1 transcription. (A,B) 
J-LatA2 cells were pre-treated with flavopiridol (A) or iCDK9 (B) for 2 hr and then treated with Amt-87 for 
24 hr at the indicated concentrations. The percentages of GFP(+) cells were determined by FACS and plotted. 
(C,D) NH1 cells were pre-treated with flavopiridol (C) or iCDK9 (D) and then treated with Amt-87 at the 
indicated concentrations for 24 hr. Whole cell extracts (WCE) were examined for luciferase activities. (E) NH1 
cells were transfected with the plasmid expressing CDK9 mutant D167N and then treated with Amt-87 for 
24 hr at the indicated concentration. WCE were examined for luciferase activities. The error bars in all panels 
represent mean ± SD from three independent experiments.
www.nature.com/scientificreports/
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Discussion
The data presented in the current study are consistent with the notion that Amt-87 promotes the reversal of HIV 
latency by activating P-TEFb as well as P-TEFb-dependent viral transcription. Surprisingly, Amt-87 is shown to 
use three different means to activate P-TEFb, namely the induction of phosphorylation on the T-loop of CDK9 at 
Thr186, the disruption of the inactive 7SK snRNP to release P-TEFb, and lastly the promotion of Tat-SEC inter-
action on the viral LTR.
The latter two events are likely interconnected and may even have a causative relationship, as the release of 
P-TEFb from 7SK snRNP is expected to increase the pool of free and active P-TEFb that can be assembled into 
the SEC and recruited by Tat to the viral promoter region. However, it is unclear whether the Amt-87-induced 
phosphorylation of CDK9 at Thr186 is mechanistically linked to the disruption of 7SK snRNP. Previously, we 
and others have shown that even though CDK9 existing in the 7SK snRNP lacks kinase activity, it is nonetheless 
already phosphorylated at Thr18650, 51, an event, by analogy to other structurally determined CDKs52, locks the 
T-loop in an open conformation to allow the access to the catalytic center by the kinase substrate, and thus makes 
CDK9 poised to become active once liberated from the 7SK snRNP.
What remains to be determined is whether the Amt-87-induced Thr186 phosphorylation contributes to or 
may even be responsible for the release of P-TEFb from 7SK snRNP. Another aspect of the Amt-87 action that is 
yet to be investigated concerns how the drug causes the phosphorylation of CDK9 and disruption of 7SK snRNP. 
Our preliminary data suggest that Amt-87 very likely triggers an unknown signaling pathway leading to these two 
events, as the incubation of the drug with purified P-TEFb and 7SK snRNP in vitro affected neither the T-loop 
phosphorylation nor 7SK snRNP integrity (Supplementary Figs S4 and S5).
Chalconoids, which exist widely in fruits, vegetables, spices and tea, have interested organic and medicinal 
chemists for many years30. This is because chalconoids and their derivatives are not only important in the biosyn-
thesis of flavonoids as both precursors and products, they also possess numerous pharmacological activities such 
as antimicrobial, anti-inflammatory, antiviral, and anticancer effects30. Here, we report a novel function of the 
chalconoid derivative, Amt-87, in the reversal of HIV latency. Using two different Jurkat cell line-based latency 
models (J-Lat and 2D10) as well as the HIV-1 LTR-driven luciferase reporter system, we provide evidence that 
Amt-87 promotes the exit of HIV proviruses from latency by stimulating viral transcription. These observations 
indicate that chalconoids can be a promising category of compounds that should be further explored to identify 
effective LRAs that can be used alone or in combination with other drugs to induce efficient reversal of HIV 
latency.
Materials and Methods
Chemistry. All reagents and chalcones 2a–2e were purchased from commercial sources and were used with-
out further purification unless otherwise indicated. Reactions, which required the use of anhydrous, inert atmos-
phere techniques, were carried out under an atmosphere of nitrogen. Column chromatography was executed 
Figure 5. Amt-87 promotes phosphorylation of CDK9 T-loop at Thr186. (A) Whole cell lysates derived 
from NH1 and J-Lat A2 cells, which were treated with (+) or without (−) Amt-87 for 24 hr, were analyzed by 
Western blotting to detect the levels of total CDK9 and CDK9 phosphorylated on Thr186 (pT186). The levels 
of pT186 were quantified by densitometry, normalized to those of total CDK9, and shown below the blots, with 
the level of pT186 in untreated cells (lanes 1 & 3) artificially set at 100%. (B) HeLa cells were pre-treated with 
flavopiridol (FLP) for 2 hr and then treated with Amt-87 for 24 hr. The levels of Pol II CTD phosphorylated 
on Ser2 (pSer2) and Spt5 phosphorylated on Thr775 (pT775) in whole cell lysates were examined by Western 
blotting and quantified by densitometry as in A and shown in below the blots.
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Figure 6. Amt-87 dissociates P-TEFb from 7SK snRNP and promotes Tat-SEC formation at the HIV-1 
promoter. (A) The HeLa-based F1C2 cells stably expressing the Flag-tagged CDK9 were treated with Amt-87 or 
DMSO for 24 hr. Nuclear extracts (NE) and anti-Flag immunoprecipitates (IP) derived from NE were analyzed 
by Western blotting for the indicated proteins and the results were quantified and shown on the right, with the 
numbers in lanes 1 and 3 set to 1. (B) NH1 cells transfected with the Tat-Flag-expressing plasmid were treated 
with Amt-87 (+) or DMSO (−) for 24 hr. NEs and anti-Flag IP derived from NE were analyzed by Western 
blotting for the indicated proteins. (C) Upon transfection with the plasmid expressing Tat-Flag for 24 hr, NH1 
cells were treated with Amt-87 or DMSO for 24 hr and then subjected to ChIP-qPCR analysis to determine 
the occupancy of the indicated factors at three different locations (1–3) at and around the HIV-1 promoter 
region (diagramed on top). The ChIP signals were normalized to those of input and plotted, with the error bars 
indicating mean ± SD from three independent experiments.
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with silica gel (60–120 or 230–400 mesh) using mixtures of ethyl acetate and hexane as eluants. Melting points 
were measured on a SGW X-4 micro-melting point spectrometer and were uncorrected. 1H-NMR and 13C-NMR 
spectra were obtained using a Bruker (Bruker Biospin, Zug, Switzerland) AV2 600 Ultrashield spectrometer at 
600 and 150 MHz, respectively. Chemical shifts were given in parts per million (ppm) relative to tetramethylsilane 
(TMS) as an internal standard. Multiplicities were abbreviated as follows: single (s), doublet (d), doublet-dou-
blet (dd), doublet-triplet (dt), triplet (t), triplet-triplet (tt), triplet-doublet (td), quartet (q), quartet-doublet (qd), 
quint (quin), sext (sxt), multiplet (m), and broad signal (br. s.). High-resolution mass spectral (HRMS) data were 
acquired using electrospray ionization (ESI) on a Q Exactive LC-MS/MS instrument (Thermo Fisher Scientific 
Inc., Waltham, MA, USA) with UV detection at 254 nm.
Synthesis. The general method for the synthesis of 2′-hydroxy-chalcone amide derivatives (1a–1p) and 
5-adamantyl-chalcones (3a–3e and 4a–4d) are outlined in Supplemental Information, with their structures con-
firmed by 1H-NMR, 13C-NMR, and HRMS (for details, see Supplemental Information).
HPLC analysis of Amt-87. The purity of Amt-87 was assessed by HPLC with a COSMOSIL C18-MS-II col-
umn (250 mm × 4.6 mm i.d., 5 mm). The mobile phase used was acetonitrile (A) and water (B) in a linear gradient 
mode as follows: A from 80% to 100% and B from 20% to 0% during 0–20 min. The HPLC analysis was performed 
at a flow rate of 1 mL/min and monitored at 254 nm and 280 nm by the Agilent HPLC system.
Biochemistry. Reagents, antibodies and cell lines. Prostratin and JQ1 were purchased from LC Laboratories 
and Cayman Chemical, respectively. Flavopindol (F3055) was purchased from Sigma. The anti-ENL (A302-
267A) and anti-ELL2 (A302-505A) antibodies were purchased from Bethyl Laboratories. The antibodies against 
α-tubulin (T9026) and Flag (F3165) were obtained from Sigma. Antibodies recognizing CycT1 (SC-8128) and 
AFF4 (14662-1-AP) were purchased from Santa Cruz Biotechnology and Proteintech, respectively. Rabbit poly-
clonal antibodies against Brd4, HEXIM1, CDK9, LARP7, pThr186 of CDK9, pSer2 of RNA Pol II and pThr775 of 
Spt5 have been described previously26, 47, 53. Rabbit total IgG (I5006) used for ChIP was purchased from Sigma. All 
the cell lines used in this study were either purchased from American Type Culture Collection (ATCC, Manassas, 
VA) or described before54.
Screening by flow cytometry. The flow cytometry-based screening was performed in J-Lat A2 cells containing 
the integrated LTR-Tat-IRES-GFP-LTR cassette38 and 2D10 cells harboring the nearly complete HIV-1 genome 
except for the nef gene that is replaced by the GFP-coding sequence39. After incubation with the indicated con-
centrations of Amt-87 or 0.1% dimeththyl sulfoxide (DMSO) as a negative control, cells were harvested and 
washed twice in 1× phosphate buffered saline (PBS) and analyzed by flow cytometer on Epics Altra (BECKMAN 
COULTER) for the percentages of cells expressing GFP.
Luciferase assay. The luciferase assay was conducted in NH1 and NH2, a pair of HeLa-based isogenic cell lines, 
both of which contain an integrated HIV-1 LTR-luciferase reporter gene but only the latter stably expresses HIV-1 
Tat40, 41. NH1 and NH2 cells were treated with different amounts of Amt-87 and for various time periods as indi-
cated or DMSO as a negative control. Cell lysates were extracted and subjected to the measurement of luciferase 
activity using a kit from Promega.
Co-immunoprecipitation (co-IP). The co-immunoprecipitation assay was performed as described16 with minor 
modifications. Briefly, to detect the dissociation of 7SK snRNP after drug treatment, nuclear extracts (NEs) 
were prepared from F1C2 cells, a HeLa-based cell line stably expressing Flag-tagged CDK953. To detect the 
drug-induced change of the SEC, NH1 cells were transfected with 20 μg pRK5M-Tat-Flag. One day later, the cells 
were treated with 200 μg/ml Amt-87 or DMSO as a control for 24 hr and then subjected to the preparation of 
NEs. For anti-Flag IP, NEs were incubated with anti-Flag agarose beads (Sigma) for 2 hr at 4 μL at a ratio of 10 μL 
beads per 100 μL NEs. After extensive washing, the eluted proteins were analyzed by Western blotting with the 
indicated antibodies.
Chromatin immunoprecipitation (ChIP) assay. The assay was performed essentially as described55 with minor 
modifications. Briefly, NH1 cells containing a stably integrated HIV-1 LTR-luciferase reporter gene were trans-
fected with the expression construct pRK5M-Tat-Flag. Twenty four hours later, the transfected cells were treated 
with Amt-87 (100 μg/ml) or DMSO for 24 hr. Cells were cross-linked with 1% formaldehyde for 10 min at room 
temperature, which was quenched by the addition of glycine to 0.125 M for 5 min. After washing in PBS, 1 × 107 
cells were re-suspended in 300 μL SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0) and frag-
mented (5 sec ON, 10 sec OFF, for a total of 20 cycles) using a Scientz JY92-IID sonicator. The lysates were diluted 
10 times with the dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 
and 167 mM NaCl), pre-cleared with Protein A or G beads (GE), and incubated with the various antibodies 
(5 μg anti-CDK9, 3 μg anti-HEXIM1, 1.5 μg anti-AFF4, 1.5 μg anti-ELL2, or 2 μg rabbit total IgG) overnight at 
4 μL. After mixing with Protein A/G beads for 1 hr, the beads were washed three times with the washing buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, and 150 mM NaCl) and then three times 
with the TE buffer (10 mM Tris-HCl, pH 8.1 and 1 mM EDTA). DNA was eluted from the beads with the elution 
buffer (1% SDS and 100 mM NaHCO3) and purified by phenol/chloroform extraction and ethanol precipitation. 
The final products were analyzed by real-time PCR with the primers listed below to amplify the integrated HIV 
LTR-luciferase gene. The PCR signals were normalized to the input DNA and shown as an average of three inde-
pendent measurements. The sequences of the primers are:
Promoter (position 1) Forward: 5′ TCCGCTGGGGACTTTCCA
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Promoter (position 1) Reverse: 5′ GTACAGGCAAAAAGCAGCTGC
TAR(position 2) Forward: 5′TGCTTTTTGCCTGTACTGGGT
TAR(position 2) Reverse: 5′CAGTACCGGAATGCCAAGCTT
Nascent (position 3) Forward: 5′ TCTGGCTAACTAGGGAACCCA
Nascent (position 3) Reverse: 5′ CGCCGGGCCTTTCTTTATGT
Data Availability. All data generated or analyzed during this study are included in this published article and 
its Supplementary Information files.
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